Longitudinal Changes in Quality of Life and Treatment Costs in Long-term Survivors of Tumors of the Oropharynx Treated with Brachytherapy or Surgery

treatment plans showed that the D95 and V95 of GTV were 66.9Gy and 98.3%, respectively. The minimum, maximum and mean dose to GTV was 54.8Gy, 77.1Gy and 69.8Gy. The mean fractional dose was 2.32Gy (1.99–2.91Gy). The average doses of the surrounding critical structures were much lower than the tolerance thresholds. Median follow-up was 12 months (range, 2–47 months). The 1-, 2and 3-year local progression-free and overall survival rates were 96.4%, 88.4%, 85.3%, and 65.9%, 49.6%, 41.6%, respectively. Eleven patients (8.3%) developed distant metastases. On univariate analysis, T stage (p 0.009), maximum reirradiation dose to GTV (p 0.006), fractional dose to GTV (p 0.02), the volume of GTV and CTV (p 0.003 & 0.004), were significant prognostic factors for overall survival. On multivariate analysis by Cox proportional hazard model, only fractional dose (p 0.029) and the volume of GTV and CTV (p 0.000) remained significant for overall survival.